Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
DYADS
1 other identifier
observational
50
1 country
1
Brief Summary
This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 15, 2020
CompletedFirst Submitted
Initial submission to the registry
October 10, 2020
CompletedFirst Posted
Study publicly available on registry
October 14, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2023
CompletedJune 29, 2025
June 1, 2025
2.2 years
October 10, 2020
June 26, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).
Based on therapy outcome measures from FEES, VoiS
t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).
Secondary Outcomes (7)
The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months)
t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months
The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only.
t = day 5, day 10, day 14, day 21 - For in-patients only.
Relationship between severity of dysphonia and/or dysphagia with grade of ARDS
t = day 0 and 9 months
Relationship between severity of dysphonia and/or dysphagia with length of intubation
t = day 0 and 9 months
Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation
t = day 0 and 9 months
- +2 more secondary outcomes
Interventions
This is the use of endoscopy during feeding trials. The patient is fed different consistencies of food and drink while an endoscope is in place (usually passed through the nasal passage and down into the throat). The endoscope provides a bird's eye view to the transit of food through the upper aero-digestive tract. This provides information from the point of food bolus formation in the mouth to the movement of the base of the tongue; the movement of pharyngeal muscles; the deflection of the epiglottis to protect the airway including the closure of the vocal cords and the passage of food into the oesophagus. Any abnormality in these steps are noted during FEES. Liquids, thickened fluids, semi-solids and solids are some of the food textures that are tested.
A radio opaque dye is used to label the test food and drink items offered to the patient. Following this, x-ray technology is used to create a video of the outline of the patient and the structures responsible for chewing and swallowing as they injest the test materials. The study is carried out in real time in the radiology department in conjunction with a radiographer and an SLT.
This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28.
Eligibility Criteria
Patients identified with dysphagia and dysphonia secondary to COVID19 infection. Specifically severely unwell patients and post-extubation patients.
You may qualify if:
- Patients who have been diagnosed with a positive SARS CoV-2 test.
- Patients who have been diagnosed with dysphonia and/or dysphagia following COVID 19 treatment.
- Patients who require investigation and management for dysphonia and/or dysphagia following COVID 19 treatment.
- Adult patients aged 18 years - 85 years.
- Patients that meet threshold for referral to the joint MDT clinic following screening
You may not qualify if:
- Patients who cannot undertake the assessment for dysphonia and/or dysphagia.
- Patients who are being managed with palliative intent.
- Patients with pre-existing dysphonia and/or dysphagia not previously responding to therapy (pre-existing prior to COVID-19 diagnosis).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Consultant Otolaryngology, Head & Neck Surgeon.
Study Record Dates
First Submitted
October 10, 2020
First Posted
October 14, 2020
Study Start
September 15, 2020
Primary Completion
November 30, 2022
Study Completion
January 30, 2023
Last Updated
June 29, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share